• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor.

作者信息

Bertuglia Giuseppe, Garibaldi Bruno, Casson Andrea, Sarina Barbara, Gay Francesca, Mercadante Silvio, Mariotti Jacopo, D'agostino Mattia, Taurino Daniela, Oliva Stefania, Larocca Alessandra, Mannina Daniele, De Philippis Chiara, Benevolo Giulia, Francisci Tiziana, Lorenzi Marco, Bruno Benedetto, Santoro Armando, Bringhen Sara, Mina Roberto, Bramanti Stefania

机构信息

Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Italy.

出版信息

Bone Marrow Transplant. 2025 Jan;60(1):79-82. doi: 10.1038/s41409-024-02432-x. Epub 2024 Oct 4.

DOI:10.1038/s41409-024-02432-x
PMID:39367227
Abstract
摘要

相似文献

1
Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor.达雷妥尤单抗对接受粒细胞集落刺激因子（G-CSF）加按需使用普乐沙福进行造血干细胞动员的多发性骨髓瘤患者采集和植入的影响
Bone Marrow Transplant. 2025 Jan;60(1):79-82. doi: 10.1038/s41409-024-02432-x. Epub 2024 Oct 4.
2
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
3
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞：一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.
4
A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.新诊断多发性骨髓瘤患者中无化疗策略与按需 G-CSF 联合普乐沙福与中剂量环磷酰胺和 G-CSF 作为 PBSC 动员的比较：意大利探索性成本分析。
Transfus Apher Sci. 2020 Oct;59(5):102819. doi: 10.1016/j.transci.2020.102819. Epub 2020 May 25.
5
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.接受基于达雷妥尤单抗诱导治疗的多发性骨髓瘤患者的干细胞动员：一项真实世界经验
Transplant Cell Ther. 2023 May;29(5):340.e1-340.e4. doi: 10.1016/j.jtct.2023.02.013. Epub 2023 Feb 19.
6
[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].[新型冠状病毒肺炎感染对多发性骨髓瘤患者自体外周血干细胞动员及采集的影响]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Apr;33(2):455-462. doi: 10.19746/j.cnki.issn.1009-2137.2025.02.021.
7
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.普乐沙福：一种趋化因子受体-4 拮抗剂，用于高剂量化疗治疗非霍奇金淋巴瘤或多发性骨髓瘤后移植造血干细胞的动员。
Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007.
8
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.超越 CD34+ 细胞剂量：外周血造血干细胞动员方法（粒细胞集落刺激因子[G-CSF]、G-CSF 加plerixafor 或环磷酰胺 G-CSF/粒细胞-巨噬细胞[GM]-CSF）对集落形成单位-GM 数量、植入和第 100 天造血移植物功能的影响。
Transfusion. 2011 Sep;51(9):1995-2000. doi: 10.1111/j.1537-2995.2011.03085.x. Epub 2011 Mar 10.
9
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.普乐沙福：在淋巴瘤或多发性骨髓瘤患者中用于干细胞动员的综述。
Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000.
10
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.在恶性淋巴瘤或多发性骨髓瘤患者中，在使用粒细胞集落刺激因子的基础上加用普乐沙福用于造血干细胞动员以进行自体移植。
Cochrane Database Syst Rev. 2015 Oct 20;2015(10):CD010615. doi: 10.1002/14651858.CD010615.pub2.

引用本文的文献

1
Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery.达雷妥尤单抗用于骨髓瘤诱导治疗时与干细胞动员受损及移植后血液学恢复延长相关。
Cancers (Basel). 2024 May 13;16(10):1854. doi: 10.3390/cancers16101854.

本文引用的文献

1
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员，并影响其集落形成能力。
Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.
2
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
3
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
达雷妥尤单抗对多发性骨髓瘤患者自体干细胞移植中干细胞动员和采集、植入和移植后早期并发症的影响。
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
4
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.接受基于达雷妥尤单抗诱导治疗的多发性骨髓瘤患者的干细胞动员：一项真实世界经验
Transplant Cell Ther. 2023 May;29(5):340.e1-340.e4. doi: 10.1016/j.jtct.2023.02.013. Epub 2023 Feb 19.
5
Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients.基于达雷妥尤单抗的诱导治疗对瑞典骨髓瘤患者干细胞采集参数的影响。
Haematologica. 2023 Feb 1;108(2):610-614. doi: 10.3324/haematol.2022.281610.
6
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.在3期CASSIOPEIA研究中，接受达雷妥尤单抗+硼替佐米/沙利度胺/地塞米松治疗的符合移植条件的新诊断多发性骨髓瘤患者的干细胞产量及移植情况
Haematologica. 2021 Aug 1;106(8):2257-2260. doi: 10.3324/haematol.2020.261842.
7
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：欧洲血液学协会-欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.
8
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
9
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.多发性骨髓瘤和淋巴瘤患者的自体造血干细胞动员：欧洲血液与骨髓移植组的立场声明
Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31.